44th American Society of Clinical Oncology (ASCO) Annual Meeting
May 30 - June 3, 2008, Chicago
|
| • |
Schedule of presentations (19K PDF) |
| |
American Association for Cancer Research Annual Meeting 2008
April 12-16, San Diego, CA
|
| • |
Application of cellular pharmacogenomics and systems biology to identify contexts of vulnerability and guide the clinical development of brostallicin (2.8M PDF) |
| • |
Brostallicin treatment impacts p53 wild-type and mutated cell lines through inhibition on cell cycle progression and apoptosis induction: in vitro and in vivo studies (337K PDF) |
| |
2007
ASH Annual Meeting and Exposition
December 8-11, 2007, Atlanta, GA
|
| • |
Activities at ASH 2007
(43K PDF) |
| • |
CHOP-R
compared to CPOP-R in first-line therapy of diffuse large
B cell lymphoma: an interim analysis (187 PDF) |
| |
AACR-NCI-EORTC
International Conference on Molecular Targets and Cancer
Therapeutics
Oct. 22-26, 2007, San Francisco, CA |
| • |
Antitumor
activity of brostallicin on human prostatic cancer: role
of combination with hypomethylating agents (237K PDF) |
| • |
BBR
3576 A 9-aza-anthrapyrazole endowed with high antitumor
activity on prostate carcinoma models (55 PDF) |
| • |
Novel bisplatinum complexes
characterized by an improved
in vitro plasma protein binding and in
vivo efficacy on xenograft
models (60K PDF) |
| • |
|
| |
ECCO 14 The European Cancer
Conference
Sept. 23-27, 2007, Barcelona, Spain |
| • |
|
| |
12th World Conference on Lung Cancer
Sept. 2-6, 2007, Seoul, Korea |
| • |
Serum cathepsin B is prognostic and may predict response
to therapy in chemotherapy-naive PS2 advanced NSCLC patients
treated on two concurrent phase III trials of paclitaxel
poliglumex vs control treatments (STELLAR 3 and 4) (116K PDF) |
| |
American Society
of Clinical Oncology (ASCO) 43rd Annual Meeting
May 31 - June 5, 2007, Chicago, IL |
| SCHEDULE OF ACTIVITIES |
| • |
Activities at ASCO
2007 (36k PDF) |
| • |
Serum free estradiol (E2)
levels are prognostic in men with chemotherapy-naïve advanced
NSCLC and PS 2 (162K PDF) |
| • |
Single-agent versus combination first-line chemotherapy
in patients with advanced non-small cell lung cancer and a
performance status of 2 (105K PDF) |
| |
American Society
of Hematology (ASH) 48th
Annual Meeting
December 2006, Orlando, FL |
| POSTERS & PRESENTATIONS |
| • |
Phase
II study of pixantrone in combination with cyclophosphamide,
vincristine, and prednisone (CPOP) in patients with relapsed
aggressive non-Hodgkin's lymphoma (141k PDF) |
| • |
Results
of a phase I/II trial of pixantrone in combination with fludarabine,
dexamethasone, and rituximab (FPD-R) in the treatment of
patients with relapsed/refractory indolent non-Hodgkin's
lymphoma (147k PDF) |
